The DOI matches its Crossref record.
How Drugs are Developed and Approved by the FDA: Current Process and Future Directions
Abstract
OBJECTIVES: This article provides an overview of FDA's regulatory processes for drug development and approval, and the estimated costs associated with the development of a drug, and also examines the issues and challenges facing the FDA in the near future. METHODS: A literature search was performed using MEDLINE to summarize the current FDA drug approval processes and future directions. MEDLINE was further utilized to search for all cost analysis studies performed to evaluate the pharmaceutical industry R&D productivity and drug development cost estimates. RESULTS: While the drug approval process remains at high risk and spans over multiple years, the FDA drug review and approval process has improved, with the median approval time for new molecular drugs been reduced from 19 months to 10 months. The overall cost to development of a drug remains quite high and has been estimated to range from $868M to $1,241M USD. Several new laws have been enacted, including the FDA Safety and Innovation Act (FDASIA) of 2013, which is designed to improve the drug approval process and enhance access to new medicines. CONCLUSIONS: The FDA's improved processes for drug approval and post-market surveillance have achieved the goal of providing patients with timely access to effective drugs while minimizing the risk of drug-related harm. The FDA drug approval process is not without controversy, as a number of well-known gastroenterology drugs have been withdrawn from the US market over the past few years. With the approval of the new FDASIA law, the FDA will continue to improve their processes and, working together with the ACG through the FDA-Related Matters Committee, continue to develop safe and effective drugs for our patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Baker, R. S., & Hawn, A. (2022) · International Journal of Artificial Intelligence in Education · doi:10.1007/s40593-021-00285-9 · Cited by 993
Cardiovascular organ-on-a-chip platforms for drug discovery and development
Ribas, J., Sadeghi, H., Manbachi, A., Leijten, J., Brinegar, K., Zhang, Y. S., Ferreira, L., & Khademhosseini, A. (2016) · Applied In Vitro Toxicology · doi:10.1089/aivt.2016.0002 · Cited by 161
Progress, obstacles, and limitations in the use of stem cells in organ-on-a-chip models
Wnorowski, A., Yang, H., & Wu, J. C. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.06.001 · Cited by 124
The Future Role of the United States in Global Health
Fuster, V., Frazer, J., Snair, M., Vedanthan, R., Dzau, V., Frazer, J., Fuster, V., Abbam, G., Batson, A., Burkle, F., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.009 · Cited by 37
Metadata
- Authors
- Ciociola, A. A., Cohen, L. B., Kulkarni, P., Kefalas, C., Buchman, A., Burke, C., Cain, T., Connor, J., Ehrenpreis, E. D., Fang, J., Fass, R., Karlstadt, R., Pambianco, D., Phillips, J., Pochapin, M., Pockros, P., Schoenfeld, P., & Vuppalanchi, R.
- Venue
- American Journal of Gastroenterology
- Published
- 2014-05
- Volume
- 109
- Issue
- 5
- Pages
- 620-623
- ISSN
- 0002-9270 (ISSN-L)
- OpenAlex
- W1971008225
- Cited by
- 162
- References
- 0
- FWCI
- 31.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: How Drugs are Developed and Approved by the FDA: Current Process and Future Directions. https://app.cochat.ai/papers/10.1038/ajg.2013.407
- The paper
- Ciociola, A. A., Cohen, L. B., Kulkarni, P., Kefalas, C., Buchman, A., Burke, C., Cain, T., Connor, J., Ehrenpreis, E. D., Fang, J., Fass, R., Karlstadt, R., Pambianco, D., Phillips, J., Pochapin, M., Pockros, P., Schoenfeld, P., & Vuppalanchi, R. (2014). How Drugs are Developed and Approved by the FDA: Current Process and Future Directions. American Journal of Gastroenterology. https://doi.org/10.1038/ajg.2013.407
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.